2 Biotech Stocks That Surged More Than 100% in September

: LPTX | Leap Therapeutics, Inc. News, Ratings, and Charts

LPTX – The biotech industry continues to play a crucial role in developing solutions to treat critical ailments. In addition, the demand for biotech solutions is also high across other sectors such as food and agriculture. So, biotech stocks such as Leap Therapeutics (LPTX) and Corvus Pharmaceuticals (CRVS), which have soared more than 100% in September, could be solid additions to your portfolio.

The biotech industry is known to be a high-risk high-reward industry. The Biden administration’s intention to enact legislation to lower drug prices was not well-received by biotech companies. However, governments and businesses have been making robust investments to encourage research and development in the biotech space.

Increasing demand for biotech applications and solutions across various end-user industries such as food, agriculture, and healthcare, plus growing demand for synthetic biology are expected to help boost the industry’s growth. According to a Research and Market’s report, the global biotechnology market is expected to grow at a CAGR of 8.57% over the next five years.

Amid this backdrop, quality biotech stocks Leap Therapeutics, Inc. (LPTX) and Corvus Pharmaceuticals, Inc. (CRVS), which have surged more than 100% last month, could be good additions to your portfolio.

Leap Therapeutics, Inc. (LPTX)

Biopharmaceutical company LPTX acquires and develops therapies to treat cancer. The company mainly develops targeted and immuno-oncology therapeutics. Its DKN-01 is an advanced humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.

On September 16, 2021, LPTX announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study. Samuel Klempner, Member of the Faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School, said, “Taken together, these are promising results for the combination therapy of DKN-01 with tislelizumab and chemotherapy in first line patients with gastric or gastroesophageal junction cancers.”

LPTX’s license revenue remained flat at $375,000 for the fiscal second quarter that ended June 30, 2021, compared to the prior year. The company’s $0.12 loss per share also remained the same. However, its total liabilities and stockholders’ equity came in at $37.94 million for the period that ended June 30, 2021, compared to $54.37 million for the period that ended December 31, 2020. In addition, its cash and cash equivalents at the beginning of the period for the six months that ended June 30, 2021, came in at $52.07 million, compared to $3.89 million for the six months that ended June 30, 2020.

For fiscal 2021, analysts expect LPTX’s revenue to increase 87.3% year-over-year to $2.81 million. Its EPS is expected to increase 25.4% year-over-year this year. The stock has soared 123.8% over the past three months and 137.8% in September to close yesterday’s trading session at $3.58.

Click here to checkout our Healthcare Sector Report for 2021

Corvus Pharmaceuticals, Inc. (CRVS)

Clinical stage biopharmaceutical company CRVS develops and commercializes immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, in Phase I/Ib clinical trial. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial.

On August 2, 2021, Richard A. Miller, M.D., Co-founder, President and CEO of CRVS, said, “We believe mupadolimab is well-positioned to improve patient outcomes based on its dual mechanism of inhibiting immunosuppressive adenosine and enhancing antibody responses to viruses, which have been shown to cause certain cancers.”

CRVS’ total assets came in at $109.39 million for the period that ended June 30, 2021, compared to $85.53 million for the period ended December 31, 2020. Its other assets came in at $3.62 million compared to $2.4 million for the same period. Its cash, cash equivalents, and marketable securities came in at $66.46 million, compared to $44.26 million in the prior-year period.

Analysts expect CRVS’ EPS to grow 21.2% year-over-year in the current quarter ending September 30, 2021. Over the past three months, the stock has gained 77.1% to close yesterday’s trading session at $4.8. Also, it has gained 117.1% in September.


LPTX shares were trading at $3.58 per share on Tuesday afternoon, down $0.00 (0.00%). Year-to-date, LPTX has gained 59.11%, versus a 17.48% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
LPTXGet RatingGet RatingGet Rating
CRVSGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Recession or Not Recession…That Is the Question

Every investor appreciates that recessions and bear markets go hand in hand. But the definition of a recession often seems more difficult to pin down. So are we in a recession? And if not, then does that mean that disaster has been averted or that the pain train is still rolling towards investors? This is an important debate because it helps us appreciate what lies ahead for the stock market (SPY). We will tackle this vital topic in this week's commentary. Read on below...

:  |  News, Ratings, and Charts

3 Active Stocks on Wall Street to Buy Right Now

Even though the U.S. stocks ended July with decent gains, growing recession fears could keep the stock market under pressure in the near term. However, despite the current market headwinds, it could be wise to invest in fundamentally sound stocks, Microsoft (MSFT), SIGA Technologies (SIGA), and Fortinet (FTNT), which have been active on Wall Street lately. Read on to learn more…

:  |  News, Ratings, and Charts

4 Big Reasons Why the Bear Rally Is Nearing an End…

The Stock Market (SPY) has put on an impressive rally over the last few weeks, leading many investors to believe that the bull is ready to resume its run. However, there are multiple reasons to believe the bear market is far from over. I lay out 4 of the main reasons below and explain how you can profit from the volatile markets that lie ahead. Read on below for more…

:  |  News, Ratings, and Charts

2 Winning Stocks to Pay Attention to This Week

Concerns over soaring inflation, the Fed’s aggressive interest rate hikes, the decline in GDP for two consecutive quarters, and a potential recession are expected to keep the stock market under pressure in the near term. Fundamentally sound and winning stocks Murphy USA (MUSA) and JAKKS Pacific (JAKK) could be good additions to your watchlist as investors prepare for a busy week of inflation data. Let’s discuss…

:  |  News, Ratings, and Charts

4 Big Reasons Why the Bear Rally Is Nearing an End…

The Stock Market (SPY) has put on an impressive rally over the last few weeks, leading many investors to believe that the bull is ready to resume its run. However, there are multiple reasons to believe the bear market is far from over. I lay out 4 of the main reasons below and explain how you can profit from the volatile markets that lie ahead. Read on below for more…

Read More Stories

More Leap Therapeutics, Inc. (LPTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All LPTX News